Systemic therapy for ovarian cancer: current status and new treatments.
about
Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancerMaintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-AnalysisCommon variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasisHER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocolInhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenTen-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review)Factors favouring long-term survival following recurrence in ovarian cancer.Molecular genetics complexity impeding research progress in breast and ovarian cancers.Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells.HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosisElastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinomaPegylated liposomal doxorubicin in the management of ovarian cancerMifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancersImmunotherapy for ovarian cancer: what's next?Emerging role of pemetrexed in ovarian cancer.Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells.Generation and characterization of an ascitogenic mesothelin-expressing tumor model.Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenograftsPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary.Repopulation of ovarian cancer cells after chemotherapyClinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerMetronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelDOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancerOral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
P2860
Q24235072-CBF29D93-B1E8-4F8F-84A5-4E90C246C005Q26781561-76DF5AAE-43AB-44BF-A9CC-81430E34A5E9Q27851688-9072A85E-1789-4579-BBFA-01AF1A27CC9DQ28307739-9C0F5DDC-B655-4D1D-BD3D-215722ABA97FQ33305210-6D28A353-9747-47EB-8D9F-2D89DEB9F0CAQ33311401-EC2D5EEE-189F-478E-9AA8-DEBE0483161AQ33628532-131A710B-209B-4AA4-966F-8755D65D56D9Q33718820-6E8C4948-7765-424A-AC2A-B393B7CB9BA3Q33727047-DBC4A4B8-BCAD-435E-A486-DB9B6E43ABB2Q33799002-9AAE4265-8E46-414D-9CD8-F201B146036FQ33857691-D524806C-05D6-4410-99CA-086186AE3E07Q33858073-3FB21F22-0B8E-4C49-AECF-4E01C7421556Q33932032-91FFE808-54AA-4749-B1C3-AF6F8FFF485DQ33967557-CFB403EA-B904-49D3-B1B9-BFBCF3401F09Q34029209-9FC824ED-4FFB-431B-81A8-14F2A05007D1Q34141798-DB8ED015-F39E-440B-BFFD-A4D56B10139FQ34187661-D77DB842-3E69-4C31-BDBB-284CD7995631Q34285363-94975E15-AE9C-4D82-B2B4-73AD428A1CDFQ34291894-24A2AD1B-D78A-40A2-8826-D81CFDDA03E0Q34442318-5F035AA8-C441-474B-97AD-4F043F049EFAQ34499040-A401C653-A891-46C5-B96D-C4031DA594B0Q34743514-E776FB14-1C97-4B71-ADD4-FEAA65991732Q35015611-26949B03-187B-4A67-8B42-98D667E75175Q35154341-37EC247A-FD63-4C5E-8D05-ECE0A1542E96Q35236067-798D6B88-2A98-48DD-A233-FF7C82FB587EQ35238502-D3D7C793-F08B-49E7-9A72-3384AE60DD0EQ35244923-3447B2CB-0665-4279-AF68-CBCB0B625C3BQ35855107-91DBBC15-66BC-4B96-A654-F3CE0316C0D1Q35913613-FFE84AE4-93AD-4F93-8235-0405F7C53B1CQ35936614-DE91D5BC-5003-462F-A18A-6FE7212DA261Q36070842-213DB4E9-33E1-4784-A9D9-E66E658743E8Q36261762-E6E2D40A-7C20-47BE-B4AB-29C391D0A56CQ36507476-21E98DFE-C522-46AC-9EC5-393082308DD4Q36725453-4F42F3CD-5B10-4C1D-A520-831DBE37F880Q36728989-CFB2585E-CBFF-41F3-A26D-0F51EECE5704Q36802689-A343FE66-9A9A-4583-A093-E507FDA21CF4Q36975149-0D1022D6-342B-4DE9-A9D1-B98E60DD569EQ37276254-C77743F9-964F-4D7D-95DC-20575DB34F12Q37282649-554A7F5F-C1AC-4D7F-A64A-33C2F6D25449Q37423291-21AB97CA-A2FF-42E1-9575-8A6F0BB8514F
P2860
Systemic therapy for ovarian cancer: current status and new treatments.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Systemic therapy for ovarian cancer: current status and new treatments.
@ast
Systemic therapy for ovarian cancer: current status and new treatments.
@en
type
label
Systemic therapy for ovarian cancer: current status and new treatments.
@ast
Systemic therapy for ovarian cancer: current status and new treatments.
@en
prefLabel
Systemic therapy for ovarian cancer: current status and new treatments.
@ast
Systemic therapy for ovarian cancer: current status and new treatments.
@en
P1433
P1476
Systemic therapy for ovarian cancer: current status and new treatments.
@en
P2093
Robert F Ozols
P356
10.1053/J.SEMINONCOL.2006.03.011
P433
P577
2006-04-01T00:00:00Z